CA2160877A1 - Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables - Google Patents

Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables

Info

Publication number
CA2160877A1
CA2160877A1 CA 2160877 CA2160877A CA2160877A1 CA 2160877 A1 CA2160877 A1 CA 2160877A1 CA 2160877 CA2160877 CA 2160877 CA 2160877 A CA2160877 A CA 2160877A CA 2160877 A1 CA2160877 A1 CA 2160877A1
Authority
CA
Canada
Prior art keywords
antisense
microparticle
oligodeoxyribonucleotide
lactic acid
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2160877
Other languages
English (en)
Inventor
Michael David Amos
Sandra Gertrude Mcelligott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDISORB TECHNOLOGIES INTERNATIONAL LP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2160877A1 publication Critical patent/CA2160877A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
CA 2160877 1993-04-19 1994-04-19 Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables Abandoned CA2160877A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4767293A 1993-04-19 1993-04-19
US08/047,672 1993-04-19

Publications (1)

Publication Number Publication Date
CA2160877A1 true CA2160877A1 (fr) 1994-10-27

Family

ID=21950303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2160877 Abandoned CA2160877A1 (fr) 1993-04-19 1994-04-19 Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables

Country Status (6)

Country Link
EP (1) EP0695170A4 (fr)
JP (1) JPH08511418A (fr)
AU (1) AU6637394A (fr)
CA (1) CA2160877A1 (fr)
NZ (1) NZ265555A (fr)
WO (1) WO1994023699A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
NZ311175A (en) * 1995-07-03 1999-11-29 Koken Co Gene preparation comprising a gene incorporated into a biocompatible carrier which preferably contains collagen
AU714584B2 (en) 1995-07-21 2000-01-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
WO1997014440A1 (fr) * 1995-10-19 1997-04-24 Johnson & Johnson Interventional Systems Conjugaison d'oligonucleotides anti-sens c-myc avec le cholesterol pour renforcer de maniere importante leur effet inhibiteur sur l'hyperplasie de la neo-intima
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0965336A1 (fr) 1995-11-09 1999-12-22 Microbiological Research Authority ADN microencapsulé s'appliquant dans des procédés de thérapie génique
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
PT1005374E (pt) * 1997-01-22 2007-07-18 Mgi Pharma Biolog Inc Micropartículas para administração de ácido nucleico
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
WO1999065531A1 (fr) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Methodes et reactifs d'administration intramusculaire d'acides nucleiques
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
ATE309788T1 (de) * 2000-12-13 2005-12-15 Merckle Gmbh Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
KR102090851B1 (ko) 2012-08-14 2020-03-19 10엑스 제노믹스, 인크. 마이크로캡슐 조성물 및 방법
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN104981236B (zh) * 2012-09-27 2019-01-22 珠海圣美生物诊断技术有限公司 刺激敏感性微粒和使用方法
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN108753766A (zh) 2013-02-08 2018-11-06 10X基因组学有限公司 多核苷酸条形码生成
CN106413896B (zh) 2014-04-10 2019-07-05 10X基因组学有限公司 用于封装和分割试剂的流体装置、系统和方法及其应用
EP3889325A1 (fr) 2014-06-26 2021-10-06 10X Genomics, Inc. Procédés d'analyse d'acides nucléiques provenant de cellules individuelles ou de populations de cellules
MX2017005267A (es) 2014-10-29 2017-07-26 10X Genomics Inc Metodos y composiciones para la secuenciacion de acidos nucleicos seleccionados como diana.
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
AU2016207023B2 (en) 2015-01-12 2019-12-05 10X Genomics, Inc. Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
WO2016137973A1 (fr) 2015-02-24 2016-09-01 10X Genomics Inc Procédés et systèmes de traitement de cloisonnement
EP3262188B1 (fr) 2015-02-24 2021-05-05 10X Genomics, Inc. Procédés pour la couverture ciblée de séquences d'acides nucléiques
WO2017024111A1 (fr) 2015-08-04 2017-02-09 The University Of Chicago Inhibiteurs du site d'entrée interne des ribosomes (ires) cacna1a/alpha1a et procédés de traitement de l'ataxie spinocérébelleuse type 6
CN108368522A (zh) * 2015-10-20 2018-08-03 10X 基因组学有限公司 用于高通量单细胞遗传操作的方法和系统
JP6954899B2 (ja) 2015-12-04 2021-10-27 １０エックス ゲノミクス，インコーポレイテッド 核酸の解析のための方法及び組成物
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
WO2017197338A1 (fr) 2016-05-13 2017-11-16 10X Genomics, Inc. Systèmes microfluidiques et procédés d'utilisation
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018140966A1 (fr) 2017-01-30 2018-08-02 10X Genomics, Inc. Procédés et systèmes de codage à barres de cellules individuelles sur la base de gouttelettes
CN109526228B (zh) 2017-05-26 2022-11-25 10X基因组学有限公司 转座酶可接近性染色质的单细胞分析
US20180340169A1 (en) 2017-05-26 2018-11-29 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
EP3775271A1 (fr) 2018-04-06 2021-02-17 10X Genomics, Inc. Systèmes et procédés de contrôle de qualité dans un traitement de cellules uniques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4919929A (en) * 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0248531A3 (fr) * 1986-05-02 1988-09-28 Southern Research Institute Acides nucléiques encapsulés
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
JPH07501204A (ja) * 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法

Also Published As

Publication number Publication date
EP0695170A4 (fr) 1998-08-19
NZ265555A (en) 1997-09-22
AU6637394A (en) 1994-11-08
EP0695170A1 (fr) 1996-02-07
WO1994023699A1 (fr) 1994-10-27
JPH08511418A (ja) 1996-12-03

Similar Documents

Publication Publication Date Title
CA2160877A1 (fr) Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables
US6555525B2 (en) Microencapsulation and sustained release of oligonucleotides
EP2072040B1 (fr) L'emploi thérapeutique des microsphères d'acide nucléique
JP5457414B2 (ja) オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
EP0696200A1 (fr) Encapsulation d'acides nucleiques avec des conjugues qui facilitent et ciblent l'absorption cellulaire et l'expression genique
Lewis et al. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P (LA-GA) copolymer microspheres in vitro
Lewis et al. Biodegradable poly (L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides
Zon Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications: Prospects for neurobiology
CN102007213B (zh) 用于预防和/或逆转新发作的自身免疫性糖尿病的基于微球的组合物
Khan et al. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain
CN1980641A (zh) 含有寡核苷酸的微球体及其在制备用于治疗1型糖尿病的药物中的应用
Lewis Biodegradable polymers for the sustained release of antisense nucleic acids
Smith CNS delivery of antisense oligodeoxynucleotides using biodegradable microspheres
Ricci et al. New approaches for the delivery of oligonucleotides (ODNs)
Koo et al. Cellular effects of antisense c-myc oligodeoxynucleotides are delivery dependent

Legal Events

Date Code Title Description
FZDE Dead